{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Niacinamide&page=2",
    "query": {
      "intervention": "Niacinamide",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Niacinamide&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T00:30:06.649Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01093222",
      "title": "Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Extrahepatic Bile Duct Adenocarcinoma",
        "Gallbladder Adenocarcinoma",
        "Gallbladder Adenocarcinoma With Squamous Metaplasia",
        "Hilar Cholangiocarcinoma",
        "Recurrent Extrahepatic Bile Duct Carcinoma",
        "Recurrent Gallbladder Carcinoma",
        "Undifferentiated Gallbladder Carcinoma",
        "Unresectable Extrahepatic Bile Duct Carcinoma",
        "Unresectable Gallbladder Carcinoma"
      ],
      "interventions": [
        {
          "name": "Erlotinib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib Tosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2010-04",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2015-06-30",
      "last_synced_at": "2026-09-29T00:30:06.649Z",
      "location_count": 141,
      "location_summary": "Tucson, Arizona • Loma Linda, California • Los Angeles, California + 95 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Marysville",
          "state": "California"
        },
        {
          "city": "Novato",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01093222"
    },
    {
      "nct_id": "NCT00801801",
      "title": "Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Squamous Cell Lung Cancer",
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Docetaxel + Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Francisco Robert,MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2008-01",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2017-05-17",
      "last_synced_at": "2026-09-29T00:30:06.649Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00801801"
    },
    {
      "nct_id": "NCT03562468",
      "title": "A Study by ChromaDex to Assess the Effects of TRU NIAGEN on Cognitive Function, Mood and Sleep in Older Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cognitive Function",
        "Mood",
        "Sleep"
      ],
      "interventions": [
        {
          "name": "300 mg/day of TRU NIAGEN (nicotinamide riboside)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "1000 mg/day of TRU NIAGEN (nicotinamide riboside)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "ChromaDex, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2018-06-13",
      "completion_date": "2019-04-26",
      "has_results": false,
      "last_update_posted_date": "2019-07-24",
      "last_synced_at": "2026-09-29T00:30:06.649Z",
      "location_count": 1,
      "location_summary": "Boca Raton, Florida",
      "locations": [
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03562468"
    },
    {
      "nct_id": "NCT01218126",
      "title": "Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "losmapimod",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 604,
      "start_date": "2010-11-04",
      "completion_date": "2011-12-21",
      "has_results": true,
      "last_update_posted_date": "2018-02-06",
      "last_synced_at": "2026-09-29T00:30:06.649Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Torrance, California • Rochester, Minnesota + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Saint Charles",
          "state": "Missouri"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01218126"
    },
    {
      "nct_id": "NCT01620216",
      "title": "Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome",
        "Chronic Myelomonocytic Leukemia",
        "Recurrent Acute Lymphoblastic Leukemia",
        "Recurrent Acute Myeloid Leukemia",
        "Refractory Acute Lymphoblastic Leukemia",
        "Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Antitumor Drug Screening Assay",
          "type": "OTHER"
        },
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Idelalisib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pacritinib",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Ponatinib",
          "type": "DRUG"
        },
        {
          "name": "Ponatinib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib Tosylate",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib Malate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2012-05-11",
      "completion_date": "2017-04-30",
      "has_results": true,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-09-29T00:30:06.649Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01620216"
    },
    {
      "nct_id": "NCT05243290",
      "title": "Nicotinamide Riboside Clinical Trial for GWI",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Gulf War Illness"
      ],
      "interventions": [
        {
          "name": "Nicotinamide Riboside",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Roskamp Institute Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "47 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "47 Years to 70 Years"
      },
      "enrollment_count": 52,
      "start_date": "2022-04-13",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-07-24",
      "last_synced_at": "2026-09-29T00:30:06.649Z",
      "location_count": 2,
      "location_summary": "Fort Lauderdale, Florida • Sarasota, Florida",
      "locations": [
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05243290"
    },
    {
      "nct_id": "NCT03821623",
      "title": "Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypertension",
        "Aging"
      ],
      "interventions": [
        {
          "name": "Nicotinamide riboside",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Douglas Seals",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 118,
      "start_date": "2019-05-10",
      "completion_date": "2025-06-01",
      "has_results": false,
      "last_update_posted_date": "2025-02-21",
      "last_synced_at": "2026-09-29T00:30:06.649Z",
      "location_count": 1,
      "location_summary": "Boulder, Colorado",
      "locations": [
        {
          "city": "Boulder",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03821623"
    },
    {
      "nct_id": "NCT01445080",
      "title": "Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Blastic Phase",
        "Childhood Acute Promyelocytic Leukemia With PML-RARA",
        "Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Childhood Solid Neoplasm",
        "Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Juvenile Myelomonocytic Leukemia",
        "Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Recurrent Disease"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Sorafenib Tosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 70,
      "start_date": "2006-05-30",
      "completion_date": "2012-12-10",
      "has_results": true,
      "last_update_posted_date": "2021-02-02",
      "last_synced_at": "2026-09-29T00:30:06.649Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Orange, California • Palo Alto, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01445080"
    },
    {
      "nct_id": "NCT02988440",
      "title": "Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "PDR001",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2017-04-20",
      "completion_date": "2020-02-27",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-09-29T00:30:06.649Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02988440"
    },
    {
      "nct_id": "NCT00590629",
      "title": "Benefit of Elevation of HDL-C on Cardiovascular Outcomes in Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Niaspan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 43,
      "start_date": "2002-06",
      "completion_date": "2005-11",
      "has_results": false,
      "last_update_posted_date": "2011-09-14",
      "last_synced_at": "2026-09-29T00:30:06.649Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00590629"
    }
  ]
}